Log in
Log in
E-mail
Password

Show password
Remember
Forgot password ?
Become a member for free
Sign up
Become a member for free
Sign up
New member
Sign up for FREE
New customer
Discover our services
  1. Homepage
  2. Equities
  3. United States
  4. Nasdaq
  5. Angion Biomedica Corp.
  6. News
  7. Summary
    ANGN   US03476J1079

ANGION BIOMEDICA CORP.

(ANGN)
  Report
Delayed Nasdaq  -  04:00 2022-08-05 pm EDT
1.090 USD   +0.93%
07/25Angion Announces Process to Explore Strategic Alternatives for Enhancing and Preserving Shareholder Value
CI
07/25ANGION BIOMEDICA CORP. : Costs Associated with Exit or Disposal Activities, Change in Directors or Principal Officers (form 8-K)
AQ
07/25Angion Biomedica Corp. Announces Resignation of John F. Neylan as Chief Medical Officer and Head of Research, Effective on August 15, 2022
CI
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news

Sector Update: Health Care Stocks Little Changed on Thursday

06/30/2022 | 02:00pm EDT
share with twitter
share with LinkedIn
share with facebook


© MT Newswires 2022
Stocks mentioned in the article
ChangeLast1st jan.
ANGION BIOMEDICA CORP. 0.93% 1.09 Delayed Quote.-62.41%
BIONTECH SE 1.48% 183.11 Delayed Quote.-28.97%
CYTOKINETICS, INCORPORATED 10.92% 51.82 Delayed Quote.13.69%
NASDAQ COMPOSITE -0.50% 12657.55 Real-time Quote.-19.10%
PFIZER, INC. -1.18% 49.27 Delayed Quote.-16.56%
UNIVERSAL HEALTH SERVICES, INC. 0.59% 110.35 Delayed Quote.-14.89%
All news about ANGION BIOMEDICA CORP.
07/25Angion Announces Process to Explore Strategic Alternatives for Enhancing and Preserving..
CI
07/25ANGION BIOMEDICA CORP. : Costs Associated with Exit or Disposal Activities, Change in Dire..
AQ
07/25Angion Biomedica Corp. Announces Resignation of John F. Neylan as Chief Medical Officer..
CI
07/25Angion Biomedica to Explore Strategic Alternatives to Boost Shareholder Value
MT
07/25Angion Announces Process to Explore Strategic Alternatives for Enhancing and Preserving..
GL
07/25Angion Announces Process to Explore Strategic Alternatives for Enhancing and Preserving..
AQ
07/18HC Wainwright Downgrades Angion Biomedica to Neutral From Buy
MT
06/30SECTOR UPDATE : Health Care Stocks Swoon Late, Closing Lower
MT
06/30Top Midday Decliners
MT
06/30SECTOR UPDATE : Health Care Stocks Little Changed on Thursday
MT
More news
Analyst Recommendations on ANGION BIOMEDICA CORP.
More recommendations
Financials (USD)
Sales 2022 3,72 M - -
Net income 2022 - - -
Net Debt 2022 - - -
P/E ratio 2022 -
Yield 2022 -
Capitalization 32,7 M 32,7 M -
Capi. / Sales 2022 8,77x
Capi. / Sales 2023 20,4x
Nbr of Employees 71
Free-Float 66,0%
Chart ANGION BIOMEDICA CORP.
Duration : Period :
Angion Biomedica Corp. Technical Analysis Chart | MarketScreener
Full-screen chart
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus HOLD
Number of Analysts 3
Last Close Price 1,09
Average target price
Spread / Average Target -
Managers and Directors
Jay R. Venkatesan Chairman, President & Chief Executive Officer
Greg S. Curhan Chief Financial Officer
John F. Neylan Chief Medical Officer, EVP & Head-Research
Jennifer J. Rhodes Secretary, Chief Compliance & Business Officer
Allen R. Nissenson Independent Director
Sector and Competitors
1st jan.Capi. (M$)
ANGION BIOMEDICA CORP.-62.41%33
MODERNA, INC.-26.44%73 092
IQVIA HOLDINGS INC.-16.94%43 781
LONZA GROUP AG-26.44%43 083
SEAGEN INC.13.72%32 426
ALNYLAM PHARMACEUTICALS, INC.28.89%26 235